Roche: Anti-Cancer Agent “Avastin®,” Application for Approval of Additional Indication of Recurrent Glioblastoma Mittwoch, 19. September 2012 - 09:40

Dear Investor,

Please find attached a press release by Chugai:

http://www.roche.com/inv-update-2012-09-19-annex.pdf

Do not hesitate to contact us for any further questions.

With best regards,

Roche Investor Relations

Dr. Karl Mahler Phone: +41 61 68-78503 e-mail: karl.mahler@roche.com

Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com

Luís Correia Ph.D. Phone: +41 61 68-75284 e-mail: luis.correia@roche.com

Tamer Farhan Ph.D. Phone: +41 61 68-82552 e-mail: tamer.farhan@roche.com

Dr. Nina Mojas Phone: +41 61 68-71300 e-mail: nina.mojas@roche.com

Elhan Webb, CFA Phone: +41 61 68-89630 e-mail: elhan.webb@roche.com

Investor Relations North America

Thomas Kudsk Larsen Phone: +1 650 467 2016 e-mail: larsen.thomas@gene.com

Nina Goworek Phone: +1 650 467 8737 e-mail: goworek.nina@gene.com

Ekaterine Kortkhonjia Ph.D. Phone: +1 650 467 5873 e-mail: kortkhonjia.ekaterine@gene.com